$MDT
Medtronic plc Stock $mdt

$mdt Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000161310318000044 Filed on November 29, 2018

Income Statement

Concept	2018 Q4	2017 Q4
Revenue	$7.481B	$7.050B
YoY Change	6.11%	-4.02%
Cost Of Revenue	$2.203B	$2.123B
YoY Change	3.77%	-8.73%
Gross Profit	$5.278B	$4.927B
YoY Change	7.12%	-1.83%
Gross Profit Margin	70.55%	69.89%
Selling, General & Admin	$2.605B	$2.539B
YoY Change	2.6%	5.09%
% of Gross Profit	49.36%	51.53%
Research & Development	$590.0M	$556.0M
YoY Change	6.12%	0.36%
% of Gross Profit	11.18%	11.28%
Depreciation & Amortization	$651.0M	$678.0M
YoY Change	-3.98%	-7.38%
% of Gross Profit	12.33%	13.76%
Operating Expenses	$3.195B	$3.095B
YoY Change	3.23%	4.21%
Operating Profit	$1.544B	$1.894B
YoY Change	-18.48%	36.75%
Interest Expense	$241.0M	$273.0M
YoY Change	-11.72%	3.41%
% of Operating Profit	15.61%	14.41%
Other Income/Expense, Net	$52.00M	-$111.0M
YoY Change	-146.85%	24.72%
Pretax Income	$1.355B	$1.728B
YoY Change	-21.59%	42.57%
Income Tax	$235.0M	-$285.0M
% Of Pretax Income	17.34%	-16.49%
Net Earnings	$1.115B	$2.017B
YoY Change	-44.72%	80.9%
Net Earnings / Revenue	14.9%	28.61%
Basic Earnings Per Share	$0.83	$1.49
Diluted Earnings Per Share	$0.82	$1.48
COMMON SHARES
Basic Shares Outstanding	1.349B shares	1.355B shares
Diluted Shares Outstanding	1.361B shares	1.366B shares

Balance Sheet

Concept	2018 Q4	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.13B	$13.53B
YoY Change	-25.09%	20.16%
Cash & Equivalents	$3.911B	$5.529B
Short-Term Investments	$6.222B	$7.997B
Other Short-Term Assets	$2.014B	$2.246B
YoY Change	-10.33%	18.77%
Inventory	$3.763B	$3.638B
Prepaid Expenses
Receivables	$5.743B	$5.752B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$21.65B	$25.16B
YoY Change	-13.95%	11.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.536B	$4.441B
YoY Change	2.14%	-9.2%
Goodwill	$38.61B	$39.08B
YoY Change	-1.21%	-6.31%
Intangibles	$20.82B	$22.63B
YoY Change	-7.98%	-15.39%
Long-Term Investments	$511.0M	$824.0M
YoY Change	-37.99%
Other Assets	$1.123B	$1.404B
YoY Change	-20.01%	8.58%
Total Long-Term Assets	$66.50B	$69.30B
YoY Change	-4.04%	-8.68%
TOTAL ASSETS
Total Short-Term Assets	$21.65B	$25.16B
Total Long-Term Assets	$66.50B	$69.30B
Total Assets	$88.15B	$94.46B
YoY Change	-6.68%	-4.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.742B	$1.718B
YoY Change	1.4%	3.56%
Accrued Expenses	$4.606B	$4.635B
YoY Change	-0.63%	4.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.343B	$3.131B
YoY Change	-57.11%	-7.01%
Total Short-Term Liabilities	$8.463B	$10.50B
YoY Change	-19.37%	9.32%
LONG-TERM LIABILITIES
Long-Term Debt	$23.67B	$25.94B
YoY Change	-8.74%	-10.58%
Other Long-Term Liabilities	$724.0M	$933.0M
YoY Change	-22.4%	-41.65%
Total Long-Term Liabilities	$724.0M	$933.0M
YoY Change	-22.4%	-41.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.463B	$10.50B
Total Long-Term Liabilities	$724.0M	$933.0M
Total Liabilities	$38.44B	$42.88B
YoY Change	-10.36%	-10.88%
SHAREHOLDERS EQUITY
Retained Earnings	$25.17B	$25.44B
YoY Change	-1.05%	-51.56%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$49.61B	$51.47B
YoY Change
Total Liabilities & Shareholders Equity	$88.15B	$94.46B
YoY Change	-6.68%	-4.01%

Cashflow Statement

Concept	2018 Q4	2017 Q4
OPERATING ACTIVITIES
Net Income	$1.115B	$2.017B
YoY Change	-44.72%	80.9%
Depreciation, Depletion And Amortization	$651.0M	$678.0M
YoY Change	-3.98%	-7.38%
Cash From Operating Activities	$1.163B	$907.0M
YoY Change	28.22%	-38.38%
INVESTING ACTIVITIES
Capital Expenditures	-$206.0M	-$246.0M
YoY Change	-16.26%	-8.21%
Acquisitions
YoY Change
Other Investing Activities	$327.0M	$6.288B
YoY Change	-94.8%	3124.62%
Cash From Investing Activities	$121.0M	$6.042B
YoY Change	-98.0%	-8376.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.730B	-6.136B
YoY Change	-71.81%	311.54%
NET CHANGE
Cash From Operating Activities	1.163B	907.0M
Cash From Investing Activities	121.0M	6.042B
Cash From Financing Activities	-1.730B	-6.136B
Net Change In Cash	-446.0M	813.0M
YoY Change	-154.86%	-983.7%
FREE CASH FLOW
Cash From Operating Activities	$1.163B	$907.0M
Capital Expenditures	-$206.0M	-$246.0M
Free Cash Flow	$1.369B	$1.153B
YoY Change	18.73%	-33.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	46000000	USD
CY2018Q4	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	1000000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-26
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2018-10-26
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001613103
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1343045417	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Medtronic plc
	dei	Entity Small Business EntitySmallBusiness	false
CY2017Q4	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	43000000	USD
	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	7000000	USD
CY2017Q4	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	15000000	USD
	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	15000000	USD
CY2018Q4	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	11000000	USD
	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	46000000	USD
CY2018Q2	mdt	Derivative Asset Liability Fair Value Gross Asset Liability DerivativeAssetLiabilityFairValueGrossAssetLiability	-140000000	USD
CY2018Q4	mdt	Derivative Asset Liability Fair Value Gross Asset Liability DerivativeAssetLiabilityFairValueGrossAssetLiability	251000000	USD
CY2018Q2	mdt	Derivative Assets And Liabilities Net Collateral Rightto Reclaim Securities DerivativeAssetsAndLiabilitiesNetCollateralRighttoReclaimSecurities	-76000000	USD
CY2018Q4	mdt	Derivative Assets And Liabilities Net Collateral Rightto Reclaim Securities DerivativeAssetsAndLiabilitiesNetCollateralRighttoReclaimSecurities	0	USD
CY2018Q2	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	0	USD
CY2018Q4	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	18000000	USD
	us-gaap	Gain Loss On Foreign Currency Cash Flow Hedge Ineffectiveness GainLossOnForeignCurrencyCashFlowHedgeIneffectiveness	0	USD
	us-gaap	Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet	0	USD
CY2018Q2	mdt	Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction	0	USD
CY2018Q4	mdt	Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction	0	USD
	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2017Q4	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	0	shares
	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	300000	shares
CY2018Q4	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	100000	shares
	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	400000	shares
	mdt	Intercompany Dividends Paid IntercompanyDividendsPaid	0	USD
CY2018Q2	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2018Q4	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2018Q2	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2018Q4	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2018Q2	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2018Q4	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2018Q2	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2018Q4	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2018Q2	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2018Q4	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2017Q4	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	8000000	USD
	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	16000000	USD
CY2018Q4	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	24000000	USD
	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	86000000	USD
	mdt	Stock Issued During Period Value Share Based Compensation8 StockIssuedDuringPeriodValueShareBasedCompensation8	177000000	USD
	mdt	Stock Issued During Period Value Share Based Compensation8 StockIssuedDuringPeriodValueShareBasedCompensation8	744000000	USD
CY2018Q4	mdt	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	21000000	USD
	mdt	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	42000000	USD
CY2018Q4	mdt	Tax Cutsand Jobs Actof2017 Changein Tax Rate Income Tax Expense Benefit TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit	0	USD
	mdt	Tax Cutsand Jobs Actof2017 Changein Tax Rate Income Tax Expense Benefit TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit	0	USD
CY2018Q4	mdt	Tax Cutsand Jobs Actof2017 Incomplete Accounting Transition Taxfor Accumulated Foreign Earnings Provisional Liability TaxCutsandJobsActof2017IncompleteAccountingTransitionTaxforAccumulatedForeignEarningsProvisionalLiability	2500000000	USD
CY2018Q4	mdt	Tax Cutsand Jobs Actof2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsandJobsActof2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	37000000	USD
	mdt	Tax Cutsand Jobs Actof2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsandJobsActof2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	-13000000	USD
CY2017Q4	mdt	Tax Expense Benefit Associated With Saleof Intellectual Property TaxExpenseBenefitAssociatedWithSaleofIntellectualProperty	-398000000	USD
	mdt	Tax Expense Benefit Associated With Saleof Intellectual Property TaxExpenseBenefitAssociatedWithSaleofIntellectualProperty	-398000000	USD
CY2018Q2	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	-207000000	USD
CY2018Q4	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	133000000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1628000000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1742000000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5987000000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5743000000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	979000000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	536000000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	3051000000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2950000000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5655000000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5976000000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1786000000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2612000000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28127000000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27048000000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	198000000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	168000000	USD
CY2017Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	106000000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	198000000	USD
CY2018Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	104000000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	168000000	USD
CY2017Q4	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	74000000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	141000000	USD
CY2018Q4	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	83000000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	136000000	USD
CY2018Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	193000000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	184000000	USD
CY2017Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	460000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	914000000	USD
CY2018Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	445000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	891000000	USD
CY2018Q2	us-gaap	Assets Assets	91393000000	USD
CY2018Q4	us-gaap	Assets Assets	88150000000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	22980000000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	21653000000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	165000000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	166000000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	6963000000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	6419000000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	2479000000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	2568000000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	116000000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1103000000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	6820000000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	6266000000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	24000000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	25000000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	15000000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	9000000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	246000000	USD
CY2017Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	242000000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	190000000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	173000000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	208000000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	203000000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4967000000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5529000000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3669000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3911000000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	562000000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	242000000	USD
	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	118000000	USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.46
CY2017Q4	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.46
CY2018Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.46
CY2018Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.46
CY2018Q3	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.50
CY2018Q4	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.50
CY2017Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.46
CY2017Q4	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.46
CY2018Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.46
CY2018Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.46
CY2018Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2018Q4	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2600000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2600000000	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1354218154	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1346179202	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1354218154	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1346179202	shares
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2017Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1881000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3586000000	USD
CY2018Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	826000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1317000000	USD
CY2017Q4	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4000000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-11000000	USD
CY2018Q4	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	2000000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	4000000	USD
CY2017Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1877000000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	3575000000	USD
CY2018Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	828000000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1321000000	USD
CY2018Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	289000000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	280000000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	126000000	USD
CY2017Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2123000000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4475000000	USD
CY2018Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2203000000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4407000000	USD
CY2017Q2	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	296000000	USD
CY2018Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	24500000000.0	USD
CY2018Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	24500000000.0	USD
CY2018Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-120000000	USD
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-112000000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	891000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	1772000000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	58000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	104000000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	4094000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	3234000000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	107000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	62000000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	11000000	USD
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	19000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	2000000	USD
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	8000000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	11000000	USD
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	14000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	12000000	USD
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	19000000	USD
CY2018Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1988000000	USD
CY2018Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1663000000	USD
CY2018Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	107000000	USD
CY2018Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	100000000	USD
CY2018Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1465000000	USD
CY2018Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1414000000	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1423000000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1325000000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-830000000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-80000000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1314000000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1317000000	USD
CY2018Q2	us-gaap	Derivative Asset Not Offset Policy Election Deduction DerivativeAssetNotOffsetPolicyElectionDeduction	71000000	USD
CY2018Q4	us-gaap	Derivative Asset Not Offset Policy Election Deduction DerivativeAssetNotOffsetPolicyElectionDeduction	38000000	USD
CY2018Q2	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	0	USD
CY2018Q4	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	18000000	USD
CY2018Q2	us-gaap	Derivative Collateral Obligation To Return Securities DerivativeCollateralObligationToReturnSecurities	0	USD
CY2018Q4	us-gaap	Derivative Collateral Obligation To Return Securities DerivativeCollateralObligationToReturnSecurities	0	USD
CY2018Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	USD
CY2018Q4	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	USD
CY2018Q2	us-gaap	Derivative Collateral Right To Reclaim Securities DerivativeCollateralRightToReclaimSecurities	76000000	USD
CY2018Q4	us-gaap	Derivative Collateral Right To Reclaim Securities DerivativeCollateralRightToReclaimSecurities	0	USD
CY2018Q2	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	-64000000	USD
CY2018Q4	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	233000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	118000000	USD
CY2018Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	321000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	47000000	USD
CY2018Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	265000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	258000000	USD
CY2018Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	70000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	111000000	USD
CY2018Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	32000000	USD
CY2018Q2	us-gaap	Derivative Liability Not Offset Policy Election Deduction DerivativeLiabilityNotOffsetPolicyElectionDeduction	71000000	USD
CY2018Q4	us-gaap	Derivative Liability Not Offset Policy Election Deduction DerivativeLiabilityNotOffsetPolicyElectionDeduction	38000000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1247000000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1351000000	USD
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.23
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.62
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.21
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.61
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	70000000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-84000000	USD
CY2017Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.165
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.034
CY2018Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.173
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.133
CY2017Q4	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	32000000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	57000000	USD
CY2018Q4	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	21000000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	32000000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8201000000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9032000000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1692000000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	852000000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1526000000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1568000000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1636000000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1676000000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29434000000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29380000000	USD
CY2017Q4	us-gaap	Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet	0	USD
	us-gaap	Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet	0	USD
CY2018Q4	us-gaap	Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet	0	USD
CY2017Q4	us-gaap	Gain Loss On Foreign Currency Cash Flow Hedge Ineffectiveness GainLossOnForeignCurrencyCashFlowHedgeIneffectiveness	0	USD
CY2018Q4	us-gaap	Gain Loss On Foreign Currency Cash Flow Hedge Ineffectiveness GainLossOnForeignCurrencyCashFlowHedgeIneffectiveness	0	USD
	us-gaap	Gain Loss On Foreign Currency Cash Flow Hedge Ineffectiveness GainLossOnForeignCurrencyCashFlowHedgeIneffectiveness	0	USD
CY2017Q4	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-33000000	USD
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-122000000	USD
CY2018Q4	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	60000000	USD
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	201000000	USD
CY2017Q4	us-gaap	Gain Loss On Interest Rate Fair Value Hedge Ineffectiveness GainLossOnInterestRateFairValueHedgeIneffectiveness	0	USD
	us-gaap	Gain Loss On Interest Rate Fair Value Hedge Ineffectiveness GainLossOnInterestRateFairValueHedgeIneffectiveness	0	USD
CY2018Q4	us-gaap	Gain Loss On Interest Rate Fair Value Hedge Ineffectiveness GainLossOnInterestRateFairValueHedgeIneffectiveness	0	USD
	us-gaap	Gain Loss On Interest Rate Fair Value Hedge Ineffectiveness GainLossOnInterestRateFairValueHedgeIneffectiveness	0	USD
CY2017Q4	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	697000000	USD
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	697000000	USD
CY2018Q4	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2018Q2	us-gaap	Goodwill Goodwill	39543000000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	38605000000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	60000000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-998000000	USD
CY2017Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q4	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q4	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	61000000	USD
CY2017Q4	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2018Q4	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1728000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2923000000	USD
CY2018Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1355000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2535000000	USD
CY2017Q4	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2018Q4	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2017Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-285000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-99000000	USD
CY2018Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	235000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	338000000	USD
CY2017Q4	us-gaap	Income Tax Reconciliation Disposition Of Business IncomeTaxReconciliationDispositionOfBusiness	-6000000	USD
	us-gaap	Income Tax Reconciliation Disposition Of Business IncomeTaxReconciliationDispositionOfBusiness	54000000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	941000000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	68000000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	674000000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	37000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-307000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	24000000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	273000000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	312000000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	694000000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	499000000	USD
CY2017Q4	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3000000	shares
	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3500000	shares
CY2018Q4	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3100000	shares
	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3300000	shares
CY2017Q4	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7700000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8500000	shares
CY2018Q4	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8500000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8400000	shares
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21723000000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20819000000	USD
CY2017Q4	us-gaap	Interest Expense InterestExpense	273000000	USD
	us-gaap	Interest Expense InterestExpense	559000000	USD
CY2018Q4	us-gaap	Interest Expense InterestExpense	241000000	USD
	us-gaap	Interest Expense InterestExpense	483000000	USD
	us-gaap	Interest Paid Net InterestPaidNet	587000000	USD
	us-gaap	Interest Paid Net InterestPaidNet	482000000	USD
CY2018Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2407000000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2479000000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	3579000000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	3763000000	USD
CY2018Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	676000000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	722000000	USD
CY2018Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	496000000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	562000000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	40571000000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	38436000000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91393000000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88150000000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10084000000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8463000000	USD
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	23699000000	USD
CY2018Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	23673000000	USD
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2058000000	USD
CY2018Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1343000000	USD
CY2018Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	25100000000	USD
CY2018Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	24800000000	USD
CY2018Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	900000000	USD
CY2018Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	900000000	USD
CY2017Q4	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
CY2018Q4	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	103000000	USD
CY2018Q2	us-gaap	Minority Interest MinorityInterest	102000000	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	107000000	USD
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-2000000	USD
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	1000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7277000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3303000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6125000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	764000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1644000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2865000000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	2017000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3033000000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	1115000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	2190000000	USD
CY2017Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11000000	USD
CY2018Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5000000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	7000000	USD
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2017000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3033000000	USD
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1115000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2190000000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	1894000000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	3276000000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	1544000000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	2780000000	USD
CY2018Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2187000000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2014000000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1078000000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1123000000	USD
CY2017Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-203000000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	628000000	USD
CY2018Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-431000000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1255000000	USD
CY2017Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-136000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	553000000	USD
CY2018Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-292000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-876000000	USD
CY2017Q4	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-15000000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-14000000	USD
CY2018Q4	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-21000000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-48000000	USD
CY2017Q4	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	27000000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-144000000	USD
CY2018Q4	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	127000000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	340000000	USD
CY2017Q4	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	25000000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	55000000	USD
CY2018Q4	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9000000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9000000	USD
CY2018Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3431000000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3179000000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	889000000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	724000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	41000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-55000000	USD
CY2017Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	107000000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	206000000	USD
CY2018Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52000000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	238000000	USD
CY2017Q4	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-167000000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-232000000	USD
CY2018Q4	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-70000000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-221000000	USD
CY2018Q2	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0	USD
CY2018Q4	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0	USD
CY2017Q4	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
CY2018Q4	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2000000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1888000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2047000000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	1247000000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	1351000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	76000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	119000000	USD
	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1685000000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1444000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	524000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	497000000	USD
CY2018Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1425000000	USD
CY2018Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1301000000	USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6058000000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	20000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1000000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	230000000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	800000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-41000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	11000000	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-190000000	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-700000000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2354000000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2824000000	USD
CY2017Q4	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	980000000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1951000000	USD
CY2018Q4	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	804000000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1916000000	USD
CY2017Q4	us-gaap	Profit Loss ProfitLoss	2013000000	USD
	us-gaap	Profit Loss ProfitLoss	3022000000	USD
CY2018Q4	us-gaap	Profit Loss ProfitLoss	1120000000	USD
	us-gaap	Profit Loss ProfitLoss	2197000000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10259000000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10512000000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4604000000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4536000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	20000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	32000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4161000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	17000000	USD
CY2017Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	556000000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1105000000	USD
CY2018Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	590000000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1175000000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	24379000000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	25171000000	USD
CY2017Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7050000000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14440000000	USD
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7481000000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14865000000	USD
CY2018Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	600000000	USD
CY2018Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3Y
CY2017Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2539000000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5119000000	USD
CY2018Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2605000000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5202000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	198000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	168000000	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	7558000000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	6222000000	USD
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1835000000	USD
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1991000000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	50720000000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	49607000000	USD
CY2017Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50416000000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	51578000000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50822000000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	49714000000	USD
CY2017Q4	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-404000000	USD
	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-344000000	USD
CY2018Q4	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	58000000	USD
	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	29000000	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1700000000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1700000000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	170000000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1700000000	USD
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1365800000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1370800000	shares
CY2018Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1360900000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1363000000	shares
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1355100000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1358500000	shares
CY2018Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1349200000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1350900000	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. For the purpose of providing more concise consolidated statements of income, amounts previously reported in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">acquisition-related items</font><font style="font-family:inherit;font-size:10pt;"> were reclassified to</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> selling, general, and administrative expense</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other operating expense, net;</font><font style="font-family:inherit;font-size:10pt;"> amounts previously reported in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">divestiture-related items</font><font style="font-family:inherit;font-size:10pt;"> were reclassified to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">selling, general, and administrative expense;</font><font style="font-family:inherit;font-size:10pt;"> and amounts previously reported in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">interest income</font><font style="font-family:inherit;font-size:10pt;"> were reclassified to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other non-operating income, net</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">April 27, 2018</font><font style="font-family:inherit;font-size:10pt;">. The Company’s fiscal years </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> will end or ended on </font><font style="font-family:inherit;font-size:10pt;">April 26, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">April 27, 2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">April 28, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div>
	us-gaap	Fiscal Period FiscalPeriod	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s fiscal years </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> will end or ended on </font><font style="font-family:inherit;font-size:10pt;">April 26, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">April 27, 2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">April 28, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div></div>
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Matters</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. At </font><font style="font-family:inherit;font-size:10pt;">October 26, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">April 27, 2018</font><font style="font-family:inherit;font-size:10pt;">, accrued litigation was approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 billion</font><font style="font-family:inherit;font-size:10pt;">. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other liabilities</font><font style="font-family:inherit;font-size:10pt;"> on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Liability Matters</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sprint Fidelis</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to the Company's Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs' claim for punitive damages. Pretrial proceedings are underway. The Company has recognized an expense for probable and estimable damages related to this matter, and accrued expenses for this matter are included within accrued litigation as discussed above. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">INFUSE Litigation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimated law firms representing approximately </font><font style="font-family:inherit;font-size:10pt;">6,000</font><font style="font-family:inherit;font-size:10pt;"> claimants asserted or intended to assert personal injury claims against Medtronic in the U.S. state and federal courts involving the INFUSE bone graft product. As of June 1, 2017, the Company had reached agreements to settle substantially all of these claims, resolving this litigation. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Pelvic Mesh Litigation</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. </font><font style="font-family:inherit;font-size:10pt;">Two</font><font style="font-family:inherit;font-size:10pt;"> subsidiaries of Covidien supplied pelvic mesh products to </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company </font><font style="font-family:inherit;font-size:10pt;">$121 million</font><font style="font-family:inherit;font-size:10pt;"> towards the settlement of </font><font style="font-family:inherit;font-size:10pt;">11,000</font><font style="font-family:inherit;font-size:10pt;"> of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional </font><font style="font-family:inherit;font-size:10pt;">5,000</font><font style="font-family:inherit;font-size:10pt;"> claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately </font><font style="font-family:inherit;font-size:10pt;">15,800</font><font style="font-family:inherit;font-size:10pt;"> claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of November 1, 2018, the Company had reached agreements to settle approximately </font><font style="font-family:inherit;font-size:10pt;">15,100</font><font style="font-family:inherit;font-size:10pt;"> of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Litigation</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Ethicon</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sasso</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is involved in litigation in Indiana relating to certain patent and royalty disputes with Dr. Sasso under agreements originally entered into in 1999 and 2001. On November 28, 2018, a jury in Indiana state court returned a verdict against the Company for approximately </font><font style="font-family:inherit;font-size:10pt;">$112 million</font><font style="font-family:inherit;font-size:10pt;">. The Company has strong arguments to appeal the verdict and will file post-trial motions and, if necessary, appeals with the appropriate appellate courts. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable under U.S. GAAP. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Related Matters</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">INFUSE</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">West Virginia Pipe Trades and Phil Pace, on June 27, 2013 and July 3, 2013, respectively, filed putative class action complaints against Medtronic, Inc. and certain of its officers in the U.S. District Court for the District of Minnesota, alleging that the defendants made false and misleading public statements and engaged in a scheme to defraud regarding the INFUSE Bone Graft product during the period of December 8, 2010 through August 3, 2011. The matters were consolidated in September 2013, and in the consolidated complaint plaintiffs alleged a class period of September 28, 2010 through August 3, 2011. On September 30, 2015, the District Court granted defendants’ motion for summary judgment in the consolidated matters. Plaintiffs appealed the dismissal to the U.S. Court of Appeals for the Eighth Circuit, and in December of 2016 the Eighth Circuit Court reversed and remanded the case to the District Court for further proceedings. On January 30, 2018, the District Court issued an order certifying a class for the period of September 8, 2010 through June 28, 2011. In July of 2018, the parties reached an agreement to settle this matter, and in September of 2018, the Company paid the settlement amount into a qualified settlement fund to be distributed following final court approval.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">COVIDIEN ACQUISITION</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Merenstein</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Steiner</font><font style="font-family:inherit;font-size:10pt;"> matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On March 20, 2015, the District Court issued an order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, and reversed in part. On April 19, 2016 the Minnesota Supreme Court granted the Company’s petition to review the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings, which are ongoing. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">HEARTWARE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 22, 2016, the St. Paul Teachers’ Retirement Fund Association filed a putative class action complaint (the “Complaint”) in the United States District Court for the Southern District of New York against HeartWare on behalf of all persons and entities who purchased or otherwise acquired shares of HeartWare from June 10, 2014 through January 11, 2016 (the “Class Period”). The Complaint was amended on June 29, 2016 and claims HeartWare and one of its executives violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making false and misleading statements about, among other things, HeartWare’s response to a June 2014 U.S. FDA warning letter, the development of the Miniaturized Ventricular Assist Device (MVAD) System and the proposed acquisition of Valtech Cardio Ltd. The Complaint seeks to recover damages on behalf of all purchasers or acquirers of HeartWare’s stock during the Class Period. In August of 2016, the Company acquired HeartWare. In October of 2018, the parties reached an agreement to settle this matter. The Company's accrued expenses for this matter are included within accrued litigation as discussed above.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Environmental Proceedings</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> landfills, capping of the remaining </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> landfills, installation of a groundwater extraction system and long-term monitoring of the site and the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> remaining landfills.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following a trial in March 2002, the Court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the Court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The Court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. A third trial to determine the course of remediation to be pursued is scheduled to occur in October of 2019.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since 2011, the Company or one of its predecessors, including ev3, Inc. (“ev3”), has been responding to requests from the Department of Justice and U.S. Department of Health and Human Services for information about business practices dating back to 2005 relating to several neurovascular and peripheral vascular products developed and first marketed by those predecessors. The Company has provided information in response to these requests, and in November of 2018, the Company reached agreements to resolve certain of these matters through </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> separate civil settlements and, in the case of sales of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> product, a misdemeanor plea agreement by ev3 for conduct between October 2005 and December 2009. The misdemeanor conduct ended prior to the Covidien acquisition of ev3 in 2010 and many years before the Medtronic acquisition of Covidien. The Company’s accrued expenses for the resolved matters are included within accrued litigation as discussed above. The Company continues to provide information to the Department of Justice in responding to requests that were not subject to the resolutions described above. The Company has not recognized an expense in connection with any ongoing investigation, because any such potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from the ongoing information requests. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and on June 9, 2016, issued its opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal occurred on March 14, 2018. The 8th Circuit Court of Appeals issued their opinion on August 16, 2018, and remanded the case back to the U.S. Tax Court for additional factual findings.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2007 and 2008 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2009, 2010, and 2011 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2012. The statute of limitations for Covidien’s 2013 and 2014 U.S. federal income tax returns lapsed during the first quarter of fiscal years 2018 and 2019, respectively. Covidien's fiscal year 2015 U.S. federal income tax returns are currently being audited by the IRS.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to Note </font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;"> for additional discussion of income taxes.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Guarantees</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the acquisition of Covidien, the Company has a guarantee commitment related to certain contingent tax liabilities as a party to the Tax Sharing Agreement that was entered into on June 29, 2007, between Covidien, Tyco International (now Johnson Controls), and Tyco Electronics (now TE Connectivity), associated with the spin-off from Tyco. The Tax Sharing Agreement covers certain income tax liabilities for periods prior to and including the spin-off. Medtronic’s share of the income tax liabilities for these periods is </font><font style="font-family:inherit;font-size:10pt;">42 percent</font><font style="font-family:inherit;font-size:10pt;">, with Johnson Controls and TE Connectivity share being </font><font style="font-family:inherit;font-size:10pt;">27 percent</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">31 percent</font><font style="font-family:inherit;font-size:10pt;">, respectively. If Johnson Controls and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. The most significant amounts at risk under this Tax Sharing Agreement were resolved with the U.S. Tax Court and IRS Appeals resolutions reached in May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution, including certain state and international tax matters that remain open.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to tax years that remain open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or Tyco Electronics legal entities for periods prior to the 2007 separation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to Note 1 </font><font style="font-family:inherit;font-size:10pt;">to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 27, 2018</font><font style="font-family:inherit;font-size:10pt;"> for additional information.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the Company’s Minimally Invasive Therapies Group sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.</font></div></div>

Files In Submission

Name	View Source	Status
0001613103-18-000044-index-headers.html	Edgar Link	pending
0001613103-18-000044-index.html	Edgar Link	pending
0001613103-18-000044.txt	Edgar Link	pending
0001613103-18-000044-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mdt-20181026.xml	Edgar Link	completed
mdt-20181026.xsd	Edgar Link	pending
mdt-20181026_cal.xml	Edgar Link	unprocessable
mdt-20181026_def.xml	Edgar Link	unprocessable
mdt-20181026_lab.xml	Edgar Link	unprocessable
mdt-20181026_pre.xml	Edgar Link	unprocessable
mdt-2019q2x10q.htm	Edgar Link	pending
mdt-2019q2xex311.htm	Edgar Link	pending
mdt-2019q2xex312.htm	Edgar Link	pending
mdt-2019q2xex321.htm	Edgar Link	pending
mdt-2019q2xex322.htm	Edgar Link	pending
mdtlogo2a63.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDT
Medtronic plc Stock $mdt

2018 Q4 Form 10-Q Financial Statement

#000161310318000044 Filed on November 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT Medtronic plc Stock $mdt

2018 Q4 Form 10-Q Financial Statement

#000161310318000044 Filed on November 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT
Medtronic plc Stock $mdt